| CEO Name | Albert Bourla |
| Nationality | Greece |
| Net Worth Estimation | $35 million |
Albert Bourla's estimated net worth of around $35 million is primarily derived from his Pfizer executive salary, performance bonuses, and substantial stock ownership in the company. Additional wealth sources include investments, board memberships, and compensation from his longstanding career in the pharmaceutical industry.
Albert Bourla, CEO of Pfizer, has an estimated net worth of $35,000,000, which is 7% of the $500,000,000 maximum and 350% of the $10,000,000 minimum for pharmaceutical CEOs. His net worth places him in the lower range among top pharmaceutical CEOs.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
Albert Bourla Performance in Pfizer
Albert Bourla, CEO of Pfizer, demonstrates transformational leadership by driving innovation and strategic decision-making, notably spearheading the rapid development of the COVID-19 vaccine. His decisive actions in navigating regulatory landscapes and scaling operations boosted Pfizer's market performance and global reputation. Bourla's leadership significantly enhanced Pfizer's growth trajectory, positioning the company as a leader in biopharmaceutical innovation and public health impact.
Latest News
Pfizer's Recent Developments and CEO Albert Bourla's Leadership
Pfizer recently reported strong Q3 2025 results and raised its earnings guidance, while actively engaging in legal battles to protect its competitive position in the pharmaceutical market. CEO Albert Bourla continues to emphasize scientific innovation, defending the COVID vaccine's effectiveness and championing a "scientific renaissance" amid political challenges, as well as leading strategic agreements with the U.S. government to lower drug costs and support domestic manufacturing.
Source: http://www.pfizer.com/newsroom